Checkpoint Therapeutics: Updating My Strategy After Unloxcyt's Approval
See how Checkpoint Therapeutics, Inc.'s FDA-approved Unloxcyt drug for cSCC is set to disrupt the market with innovative ...
Silexion Therapeutics, Evonik collaborate on siRNA formulation development
Silexion Therapeutics (SLXN) revealed its ongoing collaboration with Evonik for the development of an advanced siRNA ...
GEN17h
Nvidia’s Venture Arm Raises Stake in AI Drug Discoverer Genesis Therapeutics
Through its collaboration with Nvidia, Genesis is working to accelerate development of its AI platform, Genesis Exploration ...
ETF Daily News20h
AbbVie (NYSE:ABBV) versus BriaCell Therapeutics (OTCMKTS:BCTXF) Head to Head Contrast
BriaCell Therapeutics Corp. operates as a clinical-stage biotechnology ... by conducting a Phase I/IIA clinical trial with Bria-IMT in combination with an immune checkpoint inhibitor and a companion ...
iTeos Therapeutics: A Perhaps Unjustified Decline To End 2024
Teos Therapeutics has potential lung cancer treatment despite issues and strong financial position. Read here to know why we ...
bovnews22h
Checkpoint Therapeutics Inc (CKPT) Stock: More Robust Than the Numbers Suggest?
Checkpoint Therapeutics Inc (CKPT) stock saw a decline, ending the day at $3.39 which represents a decrease of $-0.28 or -7.63% from the prior close of $3.67. The stock opened at $4 and touched a low ...